OTHER GROUP COMPANIES
market

Piramal Enterprises Q2 PAT slips 33.29% to Rs426cr; stock slumps 3%

We successfully completed the acquisition and merger of DHFL and the total AUM has grown 42% QoQ to Rs66,986cr, Ajay Piramal, Chairman, Piramal Enterprises said.

November 12, 2021 2:01 IST | India Infoline News Service
Piramal Enterprises Limited (PEL) on Thursday has announced its consolidated results for the Second Quarter (Q2) and Half Year (H1) FY2022 ended 30th September 2021.

The net profit declined 33.29% to Rs419.17cr in the quarter ended September 2021 as against Rs628.31cr during the previous quarter ended September 2020.

The sales also fell 5.95% to Rs3105.52cr in the quarter ended September 2021 as against Rs3301.84cr during the previous quarter ended September 2020.

The stock is currently trading at Rs2,622 down by Rs92.05 or 3.39% from its previous closing of Rs2,714.05 on the BSE.

Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “The second quarter of FY22 was transformational for our company and has significantly strengthened the foundation to support future growth. We successfully completed the acquisition and merger of DHFL and the total AUM has grown 42% QoQ to Rs66,986cr. The acquisition has enabled us to diversify our loan book and scale up our retail lending portfolio through multi-product offerings that cater to the needs of the underserved customers of our country. Leveraging our data, analytics and technology capabilities, we aim to be a dominant player in the growing Tier 2-3 cities and be the lender of choice for budget-conscious customers.”

Further, during the quarter, the Board of Directors approved the demerger of our pharmaceuticals business and simplification of the corporate structure. It will result in the creation of two separate listed entities in financial services and pharmaceuticals – thereby unlocking value for our shareholders. This is in line with our stated commitment as we continue to expand organically and inorganically across both the business segments. Our balance sheet strength and uniqueness of our business models sets us apart, enabling us to create long-term value for our stakeholders.”

Key Business Highlights:

Financial Services
▪ Overall AUM increased 42% QoQ to INR 66,986 Cr. post the DHFL merger
- Retail loan book increased 4.3x QoQ to INR 22,273 Cr. as of Sep-2021
- Share of retail loans increased from 11% in Jun-2021 to 33% in Sep-2021
▪ DHFL acquisition further improved ALM
- Acquisition partly funded by 10-year NCDs worth INR 19,550 Cr. at 6.75% p.a.
▪ Improvement in asset quality metrics post the DHFL acquisition - Gross NPA ratio declined 140 bps QoQ at 2.9%
- Net NPA ratio also fell 75 bps QoQ to 1.5%

Pharma
▪ Revenue grew by 20% YoY to INR 2,983 Cr. for H1 FY2022:
- India Consumer Healthcare Revenues were up 54% YoY
- Complex Hospital Generics Revenues were up 26% YoY
- CDMO Revenues were up 11% YoY
▪ Investing organically and inorganically across all our Pharma businesses in H1 FY22:
- Completed acquisition of Hemmo Pharmaceuticals for INR 775 Cr.
- Riverview facility expansion of US$ 35 Mn commenced - Aurora facility expansion of $22 Mn near completion

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

OPEN A DEMAT ACCOUNT & Get
FREE Benefits worth 10,000

STOCK VIEW

PRESTIGE (NSE)

The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction

FEATURED ARTICLE

BLOGS

Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity